Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer [published online August 28, 2018]. J Clin Oncol. 2018:Jco2018783118. doi: 10.1200/JCO.2018.78.3118.
Advertisement
Articles by Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer [published online August 28, 2018]. J Clin Oncol. 2018:Jco2018783118. doi: 10.1200/JCO.2018.78.3118.
Advertisement
Latest Updated Articles
- Study Summary: Osimertinib Versus Standard EGFR-TKI Therapy in Patients With EGFR-Mutated Advanced NSCLC and Brain Metastases at Baseline
Published: November 8th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
NYC Nurses Strike Enters Day 5 Amid Staffing, Safety, and Benefit Disputes
2
5 FAQs About ICHRAs: What to Know as ACA Subsidy Extensions Stall
3
Anti-Inflammatory, Antioxidant-Rich Diets May Lower Skin Cancer Risk, Slow Biological Aging
4
Long-term CR Seen With Allo-CAR-NK Cell Therapy Plus Rituximab in Waldenstrom NHL
5
